Ascent Solar Technologies, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Ascent Solar Technologies, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2011 | Dec 31, 2011 | $3.95M | Mar 22, 2012 |
| FY2011 | Dec 31, 2010 | $2.48M | Mar 22, 2012 |
| FY2011 | Dec 31, 2009 | $1.46M | Mar 22, 2012 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $76.8K | Mar 20, 2026 |
| FY2025 | Dec 31, 2024 | $41.9K | Mar 20, 2026 |
| FY2024 | Dec 31, 2023 | $458.3K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $1.22M | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | $607.8K | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | $66.6K | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | $638.4K | May 14, 2021 |
| FY2019 | Dec 31, 2018 | $862.4K | Jan 29, 2021 |
| FY2018 | Dec 31, 2017 | $642.2K | Apr 16, 2019 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $642.2K | Mar 29, 2018 |
| FY2017 | Dec 31, 2016 | $1.75M | Mar 29, 2018 |
| FY2016 | Dec 31, 2015 | $6.54M | Apr 17, 2017 |
| FY2015 | Dec 31, 2014 | $5.34M | Mar 11, 2016 |
| FY2013 | Dec 31, 2013 | $582.0K | Mar 28, 2014 |
| FY2013 | Sep 30, 2013 | $275.0K | Mar 28, 2014 |
| FY2013 | Jun 30, 2013 | $225.0K | Mar 28, 2014 |
| FY2013 | Mar 31, 2013 | $235.0K | Mar 28, 2014 |
| FY2013 | Dec 31, 2012 | $45.0K | Mar 28, 2014 |
| FY2013 | Sep 30, 2012 | $556.0K | Mar 28, 2014 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($7.83M) | Mar 20, 2026 |
| FY2025 | Dec 31, 2024 | ($9.13M) | Mar 20, 2026 |
| FY2024 | Dec 31, 2023 | ($17.07M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($19.75M) | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | ($6.00M) | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | $1.62M | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | ($4.87M) | May 14, 2021 |
| FY2019 | Dec 31, 2018 | ($16.04M) | Jan 29, 2021 |
| FY2018 | Dec 31, 2017 | ($18.56M) | Apr 16, 2019 |
| FY2017 | Dec 31, 2016 | ($38.85M) | Mar 29, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($7.87M) | Mar 20, 2026 |
| FY2025 | Dec 31, 2024 | ($8.54M) | Mar 20, 2026 |
| FY2024 | Dec 31, 2023 | ($15.64M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($17.06M) | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | ($8.79M) | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | ($2.45M) | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | ($3.25M) | May 14, 2021 |
| FY2019 | Dec 31, 2018 | ($6.57M) | Jan 29, 2021 |
| FY2018 | Dec 31, 2017 | ($14.15M) | Apr 16, 2019 |
| FY2017 | Dec 31, 2016 | ($24.63M) | Mar 29, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.44M | Mar 20, 2026 |
| FY2025 | Dec 31, 2024 | $2.30M | Mar 20, 2026 |
| FY2024 | Dec 31, 2023 | $3.22M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $5.98M | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | $4.14M | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | $1.17M | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | $1.31M | May 14, 2021 |
| FY2019 | Dec 31, 2018 | $2.79M | Jan 29, 2021 |
| FY2018 | Dec 31, 2017 | $4.82M | Apr 16, 2019 |
| FY2017 | Dec 31, 2016 | $6.63M | Mar 29, 2018 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.10M | Mar 20, 2026 |
| FY2025 | Dec 31, 2024 | $4.51M | Mar 20, 2026 |
| FY2024 | Dec 31, 2023 | $5.36M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $4.74M | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | $3.30M | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | $1.03M | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | $1.85M | May 14, 2021 |
| FY2019 | Dec 31, 2018 | $3.24M | Jan 29, 2021 |
| FY2018 | Dec 31, 2017 | $5.60M | Apr 16, 2019 |
| FY2017 | Dec 31, 2016 | $10.30M | Mar 29, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($6.90M) | Mar 20, 2026 |
| FY2025 | Dec 31, 2024 | ($8.42M) | Mar 20, 2026 |
| FY2024 | Dec 31, 2023 | ($9.54M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($10.51M) | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | ($9.40M) | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | ($2.88M) | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | ($2.72M) | May 14, 2021 |
| FY2019 | Dec 31, 2018 | ($4.02M) | Jan 29, 2021 |
| FY2018 | Dec 31, 2017 | ($12.60M) | Apr 16, 2019 |
| FY2017 | Dec 31, 2016 | ($16.86M) | Mar 29, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $32.0K | Mar 20, 2026 |
| FY2025 | Dec 31, 2024 | $421 | Mar 20, 2026 |
| FY2024 | Dec 31, 2023 | $3.86M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $169.4K | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | $280.3K | Mar 10, 2023 |
| FY2020 | Dec 31, 2019 | $6.4K | May 14, 2021 |
| FY2018 | Dec 31, 2018 | $0 | Apr 16, 2019 |
| FY2018 | Dec 31, 2017 | $6.4K | Apr 16, 2019 |
| FY2017 | Dec 31, 2016 | $51.7K | Mar 29, 2018 |
| FY2016 | Dec 31, 2015 | $29.2K | Apr 17, 2017 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.33M | Mar 20, 2026 |
| FY2025 | Dec 31, 2024 | $7.15M | Mar 20, 2026 |
| FY2024 | Dec 31, 2023 | $6.30M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $18.68M | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | $12.85M | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | $7.37M | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | $5.63M | May 14, 2021 |
| FY2019 | Dec 31, 2018 | $6.29M | Jan 29, 2021 |
| FY2018 | Dec 31, 2017 | $7.78M | Apr 16, 2019 |
| FY2017 | Dec 31, 2016 | $11.61M | Mar 29, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.99M | Mar 20, 2026 |
| FY2025 | Dec 31, 2024 | $3.77M | Mar 20, 2026 |
| FY2024 | Dec 31, 2023 | $7.83M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $14.09M | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | $15.68M | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | $27.56M | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | $30.74M | May 14, 2021 |
| FY2018 | Dec 31, 2018 | $28.93M | Apr 16, 2019 |
| FY2018 | Dec 31, 2017 | $20.17M | Apr 16, 2019 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.34M | Mar 20, 2026 |
| FY2025 | Dec 31, 2024 | $3.38M | Mar 20, 2026 |
| FY2025 | Dec 31, 2023 | ($1.53M) | Mar 20, 2026 |
| FY2024 | Dec 31, 2022 | $899.3K | Mar 31, 2025 |
| FY2023 | Dec 31, 2021 | ($2.83M) | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | ($20.19M) | Mar 10, 2023 |
| FY2021 | Dec 31, 2019 | ($25.11M) | Mar 14, 2022 |
| FY2020 | Dec 31, 2018 | ($22.64M) | May 14, 2021 |
| FY2019 | Dec 31, 2017 | ($15.20M) | Jan 29, 2021 |
| FY2018 | Dec 31, 2016 | ($13.99M) | Apr 16, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($499.44M) | Mar 20, 2026 |
| FY2025 | Dec 31, 2024 | ($491.61M) | Mar 20, 2026 |
| FY2024 | Dec 31, 2023 | ($482.48M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($447.54M) | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | ($427.78M) | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | ($421.78M) | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | ($423.40M) | May 14, 2021 |
| FY2019 | Dec 31, 2018 | ($418.53M) | Jan 29, 2021 |
| FY2018 | Dec 31, 2017 | ($402.50M) | Apr 16, 2019 |
| FY2017 | Dec 31, 2016 | ($383.93M) | Mar 29, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.79M | Mar 20, 2026 |
| FY2025 | Dec 31, 2024 | $3.17M | Mar 20, 2026 |
| FY2024 | Dec 31, 2023 | $1.05M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $11.48M | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | $5.96M | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | $167.7K | Mar 14, 2022 |
| FY2019 | Dec 31, 2018 | $18.2K | Jan 29, 2021 |
| FY2018 | Dec 31, 2017 | $89.6K | Apr 16, 2019 |
| FY2018 | Dec 31, 2016 | $130.9K | Apr 16, 2019 |
| FY2017 | Dec 31, 2015 | $326.2K | Mar 29, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Jan 1, 2020 | $5.89M | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | $5.89M | May 14, 2021 |
| FY2021 | Aug 2, 2019 | $5.89M | Mar 14, 2022 |
| FY2019 | Dec 31, 2018 | $5.38M | Jan 29, 2021 |
| FY2018 | Dec 31, 2017 | $5.46M | Apr 16, 2019 |
| FY2016 | Dec 31, 2016 | $5.70M | Apr 17, 2017 |
| FY2015 | Dec 31, 2015 | $5.79M | Mar 11, 2016 |
| FY2014 | Dec 31, 2014 | $6.07M | Mar 18, 2015 |
| FY2013 | Dec 31, 2013 | $6.35M | Mar 28, 2014 |
| FY2012 | Dec 31, 2012 | $6.62M | Mar 14, 2013 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (3) | Mar 20, 2026 |
| FY2025 | Dec 31, 2024 | (10) | Mar 20, 2026 |
| FY2024 | Dec 31, 2023 | (3,419) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | (132) | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | (1) | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | 1 | Mar 14, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (3) | Mar 20, 2026 |
| FY2025 | Dec 31, 2024 | (10) | Mar 20, 2026 |
| FY2024 | Dec 31, 2023 | (3,419) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | (132) | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | (1) | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 14, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 4.66M | Mar 20, 2026 |
| FY2025 | Dec 31, 2024 | 1.45M | Mar 20, 2026 |
| FY2024 | Dec 31, 2023 | 238,996 | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 259,323 | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | 4.79M | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | 3.66M | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | 4.76B | May 14, 2021 |
| FY2019 | Dec 31, 2018 | 63.54M | Jan 29, 2021 |
| FY2018 | Jul 21, 2018 | 19.00M | Apr 16, 2019 |
| FY2018 | Dec 31, 2017 | 9.61M | Apr 16, 2019 |